Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
Simpson-Yap S, Pirmani A, De Brouwer E, Peeters LM, Geys L, Parciak T, Helme A, Hillert J, Moreau Y, Edan G, Spelman T, Sharmin S, McBurney R, Schmidt H, Bergmann A, Braune S, Stahmann A, Middleton R, Salter A, Bebo B, van der Walt A, Butzkueven H, Ozakbas S, Karabudak R, Boz C, Alroughani R, Rojas JI, van der Mei I, Sciascia do Olival G, Magyari M, Alonso R, Nicholas R, Chertcoff A, Zabalza A, Arrambide G, Nag N, Descamps A, Costers L, Dobson R, Miller A, Rodrigues P, Prčkovska V, Comi G, Kalincik T. Simpson-Yap S, et al. Among authors: karabudak r. Mult Scler Relat Disord. 2022 Oct;66:104072. doi: 10.1016/j.msard.2022.104072. Epub 2022 Jul 25. Mult Scler Relat Disord. 2022. PMID: 35917745 Free PMC article.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Devonshire V, et al. Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Lancet Neurol. 2012. PMID: 22494956 Clinical Trial.
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Wolinsky JS, et al. Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27. Mult Scler. 2013. PMID: 23447359 Free article. Clinical Trial.
Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi IA, AlTahan AM, Bohlega SA, Daif A, Deleu D, Amous A, Inshasi JS, Rieckmann P, Sahraian MA, Yamout BI. Karabudak R, et al. Mult Scler Relat Disord. 2015 May;4(3):192-201. doi: 10.1016/j.msard.2015.03.004. Epub 2015 Mar 23. Mult Scler Relat Disord. 2015. PMID: 26008936 Review.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?
Dahdaleh M, Alroughani R, Aljumah M, AlTahan A, Alsharoqi I, Bohlega SA, Daif A, Deleu D, Inshasi J, Karabudak R, Sahraian MA, Taha K, Yammout BI, Zakaria M. Dahdaleh M, et al. Among authors: karabudak r. Int J Neurosci. 2017 Oct;127(10):944-951. doi: 10.1080/00207454.2016.1277424. Epub 2017 Jan 12. Int J Neurosci. 2017. PMID: 28029270 Review.
Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.
Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S. Alroughani R, et al. Among authors: karabudak r. Mult Scler Int. 2016;2016:1034912. doi: 10.1155/2016/1034912. Epub 2016 Dec 18. Mult Scler Int. 2016. PMID: 28078140 Free PMC article. Review.
Validity and reliability of the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) in multiple sclerosis patients with ataxia.
Salcı Y, Fil A, Keklicek H, Çetin B, Armutlu K, Dolgun A, Tuncer A, Karabudak R. Salcı Y, et al. Among authors: karabudak r. Mult Scler Relat Disord. 2017 Nov;18:135-140. doi: 10.1016/j.msard.2017.09.032. Epub 2017 Sep 29. Mult Scler Relat Disord. 2017. PMID: 29141795
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Kalincik T, et al. Among authors: karabudak r. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13. J Neurol Neurosurg Psychiatry. 2019. PMID: 30636699
134 results